Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Marquardt

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Theranostics|February 22, 2018
MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistanceXin Lai, Shailendra K Gupta, Ulf Schmitz, et al.
The Journal of Urology|February 21, 2016
Integrated Loss of miR-1/miR-101/miR-204 Discriminates Metastatic from Nonmetastatic Penile Carcinomas and Can Predict Patient OutcomeJuliane M Hartz, David Engelmann, Katharina Fürst, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 10, 2019
Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasivenessChristin Richter, Stephan Marquardt, Fanghua Li, et al.
Nature Communications|August 5, 2017
Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signaturesFaiz M Khan, Stephan Marquardt, Shailendra K Gupta, et al.
Cancer Letters|November 17, 2018
DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progressionKatharina Fürst, Marc Steder, Stella Logotheti, et al.
Theranostics|September 1, 2020
LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1Stella Logotheti, Stephan Marquardt, Shailendra K Gupta, et al.
Theranostics|March 15, 2019
Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic CancersDeborah Goody, Shailendra K Gupta, David Engelmann, et al.
Pharmacology & Therapeutics|June 1, 2024
Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapyStella Logotheti, Athanasia Pavlopoulou, Hamid Khoshfekr Rudsari, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Theranostics|February 22, 2018
MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistanceXin Lai, Shailendra K Gupta, Ulf Schmitz, et al.
The Journal of Urology|February 21, 2016
Integrated Loss of miR-1/miR-101/miR-204 Discriminates Metastatic from Nonmetastatic Penile Carcinomas and Can Predict Patient OutcomeJuliane M Hartz, David Engelmann, Katharina Fürst, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 10, 2019
Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasivenessChristin Richter, Stephan Marquardt, Fanghua Li, et al.
Nature Communications|August 5, 2017
Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signaturesFaiz M Khan, Stephan Marquardt, Shailendra K Gupta, et al.
Cancer Letters|November 17, 2018
DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progressionKatharina Fürst, Marc Steder, Stella Logotheti, et al.
Theranostics|September 1, 2020
LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1Stella Logotheti, Stephan Marquardt, Shailendra K Gupta, et al.
Theranostics|March 15, 2019
Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic CancersDeborah Goody, Shailendra K Gupta, David Engelmann, et al.
Pharmacology & Therapeutics|June 1, 2024
Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapyStella Logotheti, Athanasia Pavlopoulou, Hamid Khoshfekr Rudsari, et al.
Pageof 2